BUSINESS: Financial InSite Reports Second Quarter 2015 Financial Results By Staff Monday, August 17, 2015 12:23 AM ALAMEDA, Calif.—InSite Vision Incorporated (OTCBB: INSV) reported financial results for the quarter ended June 30, 2015. Revenues for the quarter ended June 30, 2015 were $0.4 million compared to $6.3 million for the same period in 2014; revenues in 2014 included a $6.0 million payment from Akorn, Inc. for an amendment to their AzaSite license agreement.“The second quarter of 2015 was marked by several notable accomplishments in the history of InSite,” said Timothy Ruane, InSite’s CEO. “After a comprehensive evaluation of opportunities to advance our late-stage assets to the next state of clinical development and provide the resources necessary for supporting these objectives, we entered into a merger agreement with QLT Inc. This merger, if consummated, will create a well-funded ophthalmic specialty pharmaceutical company with a diversified late-stage product pipeline and talented R&D team. “In June, we filed an NDA with the FDA for the marketing approval of BromSite, one of our promising product candidates, for the treatment of post-operative inflammation and the prevention of eye pain following cataract surgery. If and when the merger is consummated, the newly merged company will retain the name QLT,” Ruane said.In a related development, InSite Vision announced that the company’s Special Meeting of Stockholders to vote on certain matters in connection with the transaction with QLT Inc., including a proposal to adopt an Agreement and Plan of Merger, will be held at 10:00 a.m. Pacific Time on Sept. 30, 2015, for stockholders of record on Aug. 25, 2015. The Special Meeting will be held at InSite Vision’s headquarters at 965 Atlantic Avenue, Alameda, Calif. InSite Vision plans to mail the definitive proxy statement for the Special Meeting in early September 2015, the company said.